[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Page 51970]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22360]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Lentiviral Protein Delivery System for RNA-Guided Genome Editing

    Available for licensing and commercial development is an HIV-1-
based lentiviral vector system for gene correction strategies involving 
a homologous recombination with a variation of the CRISPR/Cas9 system. 
Other such lentivirus-based vectors encode a guide RNA, which contains 
a specific sequence that recognizes a target gene, and a Cas9 
endonuclease, which cuts at the specific site. Such systems are being 
explored as potential therapies for certain hereditary diseases (e.g., 
sickle-cell disease). However, such systems present some problems due 
to constitutive expression of Cas9 endonuclease in lentiviral vector-
transduced cells and the large size of the Cas9 gene. The variation of 
this invention delivers the Cas9 endonuclease directly, instead of the 
gene encoding the protein. This system comprises (a) a lentivirus 
vector particle comprising a lentiviral genome which encodes at least 
one guide RNA sequence that is complementary to a first DNA sequence in 
a host cell genome, (b) a Cas9 protein, and optionally (c) a donor 
nucleic acid molecule comprising a second DNA sequence. In addition, 
the invention provides a host cell comprising the foregoing system, as 
well as a method of altering a DNA sequence in a host cell comprising 
contacting a host cell with the foregoing system. Alternatively, the 
invention also provides a fusion protein comprising a Cas9 protein and 
a cyclophilin A (CypA) protein, wherein the fusion protein binds to the 
lentivirus vector particle, as well as a lentiviral vector particle 
comprising such a fusion protein. Gene correction using the disclosed 
lentiviral vector systems are being tested with respect to the beta-
globin gene and the BCL11A gene (to treat sickle-cell disease) and will 
be used for induced pluripotent stem cell (iPS) generation.
    Potential Commercial Applications:

 Sickle cell disease
 gene therapy
    Development Stage:

 Early stage

    Inventors: Naoya Uchida, Juan J. Haro Mora, John F. Tisdale (all of 
NHLBI)
    Relevant Publications: Demirci et al., Cytotherapy. 2018 
Jul;20(7):899-910. doi: 10.1016/j.jcyt.2018.04.003. Epub 2018 May 30.
    Intellectual Property: HHS Reference No. E-165-2015; U.S 
Provisional Patent Application 62/236,223 filed October 2, 2015; 
International Patent Application PCT/US2016/054759 filed September 30, 
2016, U.S. Continuation-in-Part Application 15/942,673 filed April 2, 
2018 and European Patent Application 16782163.6 having an international 
filing date of September 30, 2016.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: October 4, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-22360 Filed 10-12-18; 8:45 am]
BILLING CODE 4140-01-P